Hommerding, OliverOliverHommerdingAllory, YvesYvesAlloryArgani, PedramPedramArganiBismar, Tarek ATarek ABismarBubendorf, LukasLukasBubendorfCanete-Portillo, SofíaSofíaCanete-PortilloChaux, AlcidesAlcidesChauxChen, Ying-BeiYing-BeiChenCheng, LiangLiangChengCubilla, Antonio LAntonio LCubillaEgevad, LarsLarsEgevadGill, Anthony JAnthony JGillGrignon, David JDavid JGrignonHartmann, ArndtArndtHartmannHes, OndrejOndrejHesIdrees, Muhammad TMuhammad TIdreesKao, Chia-SuiChia-SuiKaoKnowles, Margaret AMargaret AKnowlesLooijenga, Leendert H JLeendert H JLooijengaLotan, Tamara LTamara LLotanPritchard, Colin CColin CPritchardRubin, Mark AndrewMark AndrewRubinTomlins, Scott AScott ATomlinsVan der Kwast, Theodorus HTheodorus HVan der KwastVelazquez, Elsa FElsa FVelazquezWarrick, Joshua IJoshua IWarrickWilliamson, Sean RSean RWilliamsonKristiansen, GlenGlenKristiansen2024-10-072024-10-072021-05https://boris-portal.unibe.ch/handle/20.500.12422/59219Comprehensive understanding of molecular principles in cancer and the diversification of oncological therapy promise individual therapeutic concepts, which have not yet found their way into urogenital cancer therapy. In March 2019 the International Society of Urogenital Pathology (ISUP) therefore held a consensus conference on recommendations for molecular diagnostics of genitourinary tumors, which were published in five separate manuscripts and are summarized in this article.In preparation for the conference, a comprehensive survey of current practices for molecular testing of urogenital tumors was carried out by members of the ISUP. At the conference, the results and the corresponding background information were presented by five working groups and recommendations for action for diagnostics were developed. An agreement between 66% of the conference participants was defined as consensus.deBladder cancer Kidney cancer Molecular biomarker Prostate cancer Targeted therapy600 - Technology::610 - Medicine & healtharticle10.48350/1634383339850110.1007/s00292-020-00888-4